A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

NCT01769170 ·Status: COMPLETED ·Phase: PHASE3

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1

NCT04732260 ·Status: COMPLETED ·Phase: NA

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir

NCT01651585 ·Status: COMPLETED ·Phase: PHASE4

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

NCT02439970 ·Status: TERMINATED ·Phase: PHASE3

Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women

NCT00201448 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

NCT02439957 ·Status: TERMINATED ·Phase: PHASE3

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

NCT02798692 ·Status: COMPLETED ·Phase: PHASE1

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir

NCT05446571 ·Status: RECRUITING ·Phase: PHASE3

Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

NCT01655212 ·Status: TERMINATED ·Phase: PHASE3

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

NCT00722839 ·Status: COMPLETED ·Phase: PHASE1

A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

NCT00001100 ·Status: COMPLETED ·Phase: PHASE3

CMV CTLs in Neonates With CMV Infection

NCT05564598 ·Status: RECRUITING ·Phase: PHASE2

Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

NCT02826798 ·Status: COMPLETED ·Phase: PHASE1

Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients

NCT00497796 ·Status: COMPLETED ·Phase: PHASE3

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

NCT01649869 ·Status: COMPLETED ·Phase: PHASE2

Cytomegalovirus Vaccine in Healthy Participants

NCT00712634 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

NCT01986010 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048 ·Status: COMPLETED ·Phase: PHASE1

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

NCT04975893 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

NCT05085366 ·Status: TERMINATED ·Phase: PHASE3

Recombinant CMV gB Vaccine in Postpartum Women

NCT00125502 ·Status: COMPLETED ·Phase: PHASE2

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease

NCT00004642 ·Status: COMPLETED ·Phase: PHASE1/PHASE2